{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:17:46Z","timestamp":1783977466520,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jpba.2019.01.039","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T01:44:19Z","timestamp":1548985459000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7151-3645","authenticated-orcid":false,"given":"Le","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanqi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.01.039_bib0005","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/TCRM.S143358","article-title":"A 6-year study of complicated urinary tract infections in southern China: prevalence, antibiotic resistance, clinical and economic outcomes","volume":"13","author":"Li","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jpba.2019.01.039_bib0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7164\/antibiotics.37.394","article-title":"Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli","volume":"37","author":"Hashizume","year":"1984","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.jpba.2019.01.039_bib0015","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2019.01.039_bib0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jpba.2019.01.039_bib0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jchromb.2008.09.020","article-title":"Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection","volume":"875","author":"Legrand","year":"2008","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.01.039_bib0030","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1097\/01.CCM.0000181528.88571.9B","article-title":"Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program","volume":"33","author":"Sun","year":"2005","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jpba.2019.01.039_bib0035","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/INF.0b013e31829b5880","article-title":"Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children","volume":"32","author":"Yoshizawa","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jpba.2019.01.039_bib0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2012.06.011","article-title":"Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data","volume":"40","author":"Yoshizawa","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jpba.2019.01.039_bib0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1472-8206.2003.00190.x","article-title":"Population pharmacokinetics of imipenem in burn patients","volume":"17","author":"Dailly","year":"2003","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2019.01.039_bib0050","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2019.01.039_bib0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijantimicag.2016.04.025","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection","volume":"48","author":"Kongthavonsakul","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jpba.2019.01.039_bib0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00003088-200847030-00003","article-title":"Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy","volume":"47","author":"Isla","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2019.01.039_bib0065","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/jcph.196","article-title":"Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit","volume":"54","author":"Cheatham","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl A","key":"10.1016\/j.jpba.2019.01.039_bib0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/36.suppl_A.207","article-title":"Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem","volume":"36","author":"Norrby","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2019.01.039_bib0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1155\/1998\/831425","article-title":"Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects","volume":"9","author":"Zhanel","year":"1998","journal-title":"Can. J. Infect. Dis."},{"key":"10.1016\/j.jpba.2019.01.039_bib0080","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya","year":"2016","journal-title":"Neurology"},{"issue":"Suppl. A","key":"10.1016\/j.jpba.2019.01.039_bib0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jac\/36.suppl_A.99","article-title":"Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group","volume":"36","author":"Schuler","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2019.01.039_bib0090","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1185\/030079905X46223","article-title":"Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections","volume":"21","author":"Edwards","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl. 3","key":"10.1016\/j.jpba.2019.01.039_bib0095","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1093\/clinids\/7.Supplement_3.S528","article-title":"Efficacy and safety of imipenem\/cilastatin: a review of worldwide clinical experience","volume":"7","author":"Wang","year":"1985","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.jpba.2019.01.039_bib0100","first-page":"353","article-title":"Occurrence of hepatic dysfunction and influencing factors among preadult inpatients treated with imipenem-cilastatin sodium","volume":"19","author":"Zou","year":"2017","journal-title":"Adverse Drug React. J."},{"key":"10.1016\/j.jpba.2019.01.039_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chroma.2017.04.022","article-title":"Development and validation of a quantitative confirmatory method for 30 beta-lactam antibiotics in bovine muscle using liquid chromatography coupled to tandem mass spectrometry","volume":"1500","author":"Di Rocco","year":"2017","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.01.039_bib0110","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jchromb.2011.03.038","article-title":"A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study","volume":"879","author":"Dailly","year":"2011","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.01.039_bib0115","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1128\/AAC.00533-11","article-title":"Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring","volume":"55","author":"Verdier","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2019.01.039_bib0120","series-title":"Practice of Neonatology","author":"Shao","year":"2011"},{"key":"10.1016\/j.jpba.2019.01.039_bib0125","unstructured":"RxList, Drug description of PRIMAXIN\u00ae I.V, 2018, https:\/\/www.rxlist.com\/primaxin-iv-drug.htm#description, (Accessed 23 December 2018)."},{"key":"10.1016\/j.jpba.2019.01.039_bib0130","unstructured":"RxList, Drug description of MERREM\u00ae IV, 2018, https:\/\/www.rxlist.com\/merrem-iv-drug.htm#description, (Accessed 23 December 2018)."},{"key":"10.1016\/j.jpba.2019.01.039_bib0135","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.burns.2015.01.001","article-title":"Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients","volume":"41","author":"Fournier","year":"2015","journal-title":"Burns"},{"key":"10.1016\/j.jpba.2019.01.039_bib0140","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01818-17","article-title":"Impact of real-time therapeutic drug monitoring on the prescription of antibiotics in burn patients requiring admission to the intensive care unit","volume":"62","author":"Fournier","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2019.01.039_bib0145","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jps.2600790816","article-title":"Stability and kinetics of degradation of imipenem in aqueous solution","volume":"79","author":"Smith","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2019.01.039_bib0150","first-page":"255","article-title":"Development and validation of stability-indicating HPLC method for simultaneous determination of meropenem and potassium clavulanate","volume":"71","author":"Zalewski","year":"2014","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.jpba.2019.01.039_bib0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jchromb.2007.05.043","article-title":"High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma","volume":"856","author":"Ikeda","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.01.039_bib0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0731-7085(02)00022-5","article-title":"Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC","volume":"29","author":"Robatel","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.01.039_bib0165","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1128\/AAC.00176-16","volume":"60","author":"Legrand","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2019.01.039_bib0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2019.01.039_bib0175","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","article-title":"Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa","volume":"49","author":"Tam","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2019.01.039_bib0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","article-title":"Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital","volume":"22","author":"Grant","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2019.01.039_bib0185","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00134-010-2105-0","article-title":"Optimization of meropenem dosage in the critically ill population based on renal function","volume":"37","author":"Crandon","year":"2011","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.jpba.2019.01.039_bib0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.42.3.521","article-title":"Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy","volume":"42","author":"Thomas","year":"1998","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518322301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518322301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T06:03:30Z","timestamp":1662876210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518322301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":38,"alternative-id":["S0731708518322301"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.01.039","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}